Head-to-head · Cost-Efficiency Index
NexLife vs CoraDoc
Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.
NexLife
Cost-first shoppers who want wanting a genuinely flat, dose-independent price and willing to prepay a multi-month term for the lowest advertised rate.
Visit NexLifeCoraDoc
Shoppers able to prepay a full 6-month program upfront (via Afterpay/Klarna/Affirm splits if needed) for the lowest per-month rate.
Visit CoraDocThe verdict
NexLife and CoraDoc tie on the Cost-Efficiency Index at 63/100, so neither wins outright on the numbers. For most shoppers we'd start with NexLife (ranked #185, a hair above #191) — Cost-first shoppers who want wanting a genuinely flat, dose-independent price and willing to prepay a multi-month term for the lowest advertised rate. But CoraDoc is a genuine coin-flip alternative here.
Worth knowing either way: our overall #1 pick is CoreAge Rx (Cost-Efficiency Index 94/100 — the top of the ranking). See how it stacks up: CoreAge Rx vs NexLife.
Factor by factor
Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.
Normalized Cost/Month
Price Transparency
Nationwide Access
Formulation Options
Clinical Oversight
Contract Flexibility
Pricing, coverage & formulary
The disclosed facts behind the scores. Lower price wins its row (teal).
| Spec | NexLife | CoraDoc |
|---|---|---|
| Cost-Efficiency Index | 63/100 | 63/100 |
| Semaglutide / mo | $165/mo (all doses, compounded) | $99/mo (starting dose, 6-month plan, compounded) |
| Tirzepatide / mo | $215/mo (all doses, compounded) | $149/mo (6-month plan, compounded) |
| Semaglutide / yr (modeled) | $1,980 | $1,188 |
| Tirzepatide / yr (modeled) | $2,580 | $1,788 |
| Coverage | Coverage not published | Coverage not published |
| Oral / sublingual | No | No |
| Brand-name access | Compounded only | Compounded only |
| Rank here | #185 | #191 |
NexLife
63/100Where the value is
- Flat pricing confirmed at every dose for both drugs — no per-mg escalation during titration, unlike most compounded competitors in this batch
- LegitScript certified with a named medical director (Adam Kennah, M.D.)
- States every batch undergoes independent third-party testing for potency, sterility, pH, and endotoxin levels
The tradeoffs
- The commonly advertised '$186/mo' tirzepatide headline requires a 12-month commitment; the true no-commitment month-to-month price is $215/mo — about 16% more
- No individual compounding pharmacy is named, only 'LegitScript-certified, NABP-accredited' pharmacies generically
Regulatory note: the FDA issued a warning letter to Nexlife Inc. dba Nexlife in June 2026. We still list and link to NexLife; you should know the letter is on the public record before you decide.
CoraDoc
63/100Where the value is
- Four named, board-certified providers disclosed by name — unusually transparent for this tier of provider
- LegitScript certified with a published Triple Free Promise (visit, shipping, supplies)
- Nationwide coverage including Hawaii
The tradeoffs
- The headline $99/mo price is a 6-month PREPAID program, not a month-to-month rate — 'no subscription' in CoraDoc's marketing means one large upfront payment, not low commitment, and this is easy to misread
- The actual total dollar amount charged upfront is not published in plain text — only Afterpay/Klarna 4-payment splits are shown instead of a lump total
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.